Cui Shengdong, Guo Xingran, Wang Sen, Wei Zhe, Huang Deliang, Zhang Xianzeng, Zhu Timothy C, Huang Zheng
MOE Key Laboratory of Medical Optoelectronics Science and Technology, Key Laboratory of Photonics Technology of Fujian Province, School of Optoelectronics and Information Engineering, Fujian Normal University, Fuzhou 350117, China.
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Pharmaceuticals (Basel). 2024 Sep 26;17(10):1274. doi: 10.3390/ph17101274.
Photodynamic therapy (PDT) is a therapeutic modality that depends on the interaction of light, photosensitizers, and oxygen. The photon absorption and energy transfer process can lead to the Type II photochemical reaction of the photosensitizer and the production of singlet oxygen (O), which strongly oxidizes and reacts with biomolecules, ultimately causing oxidative damage to the target cells. Therefore, O is regarded as the key photocytotoxic species accountable for the initial photodynamic reactions for Type II photosensitizers. This article will provide a comprehensive review of O properties, O production, and O detection in the PDT process. The available O data of regulatory-approved photosensitizing drugs will also be discussed.
光动力疗法(PDT)是一种依赖于光、光敏剂和氧气相互作用的治疗方式。光子吸收和能量转移过程可导致光敏剂发生II型光化学反应并产生单线态氧(O),单线态氧与生物分子发生强烈氧化反应,最终对靶细胞造成氧化损伤。因此,单线态氧被视为II型光敏剂初始光动力反应的关键光细胞毒性物质。本文将全面综述光动力疗法过程中单线态氧的性质、产生和检测。还将讨论已获监管批准的光敏药物的单线态氧相关数据。